VCN 01

Drug Profile

VCN 01

Alternative Names: VCN-01

Latest Information Update: 24 Jan 2017

Price : $50

At a glance

  • Originator VCN Biosciences
  • Class Antineoplastics; Gene therapies; Oncolytic viruses
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pancreatic cancer
  • Preclinical Retinoblastoma

Most Recent Events

  • 24 Jan 2017 Preclinical trials in Retinoblastoma in Spain (Intravitreous) before January 2017
  • 29 Nov 2016 Adverse events, efficacy, pharmacokinetics and pharmacodynamics data from a phase I trial in Solid tumours presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR - 2016)
  • 01 Feb 2016 VCN Biosciences receives grant from MINECO Spanish Government for VCN 01 development in Retinoblastoma (In infants, In children, In adolescents)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top